Clinical trial
A Randomized, Masked, Sham-Controlled Phase 2 Trial of the Safety of a Single Intravitreal Injection of jCell (Famzeretcel) for the Treatment of Retinitis Pigmentosa (RP)
NCT06912633 is registered in ClinicalTrials.gov with jCyte, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Masked, Sham-Controlled Phase 2 Trial of the Safety of a Single Intravitreal Injection of jCell (Famzeretcel) for the Treatment of Retinitis Pigmentosa (RP)
- Lead sponsor
- jCyte, Inc
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- June 20, 2025
- Completion date
- December 31, 2026
- Enrollment
- 31 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.